vs

Side-by-side financial comparison of NewtekOne, Inc. (NEWT) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $73.3M, roughly 1.7× NewtekOne, Inc.). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -2.7%). Zai Lab Ltd produced more free cash flow last quarter ($-26.7M vs $-579.3M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 12.2%).

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

NEWT vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.7× larger
ZLAB
$127.1M
$73.3M
NEWT
Growing faster (revenue YoY)
ZLAB
ZLAB
+19.8% gap
ZLAB
17.1%
-2.7%
NEWT
More free cash flow
ZLAB
ZLAB
$552.6M more FCF
ZLAB
$-26.7M
$-579.3M
NEWT
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
12.2%
NEWT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NEWT
NEWT
ZLAB
ZLAB
Revenue
$73.3M
$127.1M
Net Profit
$19.5M
Gross Margin
51.0%
Operating Margin
-54.6%
Net Margin
111.8%
Revenue YoY
-2.7%
17.1%
Net Profit YoY
6.6%
EPS (diluted)
$0.64
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$73.3M
$127.1M
Q3 25
$74.9M
$115.4M
Q2 25
$70.2M
$109.1M
Q1 25
$66.3M
$105.7M
Q4 24
$75.4M
$108.5M
Q3 24
$62.8M
$101.8M
Q2 24
$61.1M
$100.1M
Q1 24
$58.3M
$87.1M
Net Profit
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$19.5M
Q3 25
$17.9M
$-36.0M
Q2 25
$13.7M
$-40.7M
Q1 25
$9.4M
$-48.4M
Q4 24
$18.3M
Q3 24
$11.9M
$-41.7M
Q2 24
$10.9M
$-80.3M
Q1 24
$9.7M
$-53.5M
Gross Margin
NEWT
NEWT
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
NEWT
NEWT
ZLAB
ZLAB
Q4 25
-54.6%
Q3 25
-42.3%
Q2 25
-50.3%
Q1 25
-53.3%
Q4 24
-62.6%
Q3 24
-66.6%
Q2 24
-76.0%
Q1 24
-80.7%
Net Margin
NEWT
NEWT
ZLAB
ZLAB
Q4 25
111.8%
Q3 25
23.9%
-31.2%
Q2 25
19.5%
-37.3%
Q1 25
14.1%
-45.8%
Q4 24
24.3%
Q3 24
19.0%
-40.9%
Q2 24
17.9%
-80.2%
Q1 24
16.6%
-61.4%
EPS (diluted)
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$0.64
$-0.05
Q3 25
$0.67
$-0.03
Q2 25
$0.52
$-0.04
Q1 25
$0.35
$-0.04
Q4 24
$0.70
$-0.09
Q3 24
$0.45
$-0.04
Q2 24
$0.43
$-0.08
Q1 24
$0.38
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEWT
NEWT
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$689.6M
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$397.6M
$715.5M
Total Assets
$2.7B
$1.2B
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$689.6M
Q3 25
$717.2M
Q2 25
$732.2M
Q1 25
$757.3M
Q4 24
$779.7M
Q3 24
$616.1M
Q2 24
$630.0M
Q1 24
$650.8M
Total Debt
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$819.9M
Q3 25
$748.5M
Q2 25
$657.3M
Q1 25
$774.0M
Q4 24
$708.0M
Q3 24
$655.8M
Q2 24
$652.0M
Q1 24
$662.5M
Stockholders' Equity
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$397.6M
$715.5M
Q3 25
$386.7M
$759.9M
Q2 25
$312.2M
$791.7M
Q1 25
$302.3M
$810.8M
Q4 24
$296.3M
$840.9M
Q3 24
$281.8M
$667.7M
Q2 24
$274.0M
$704.2M
Q1 24
$254.1M
$762.2M
Total Assets
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$2.7B
$1.2B
Q3 25
$2.4B
$1.2B
Q2 25
$2.1B
$1.2B
Q1 25
$2.1B
$1.2B
Q4 24
$2.1B
$1.2B
Q3 24
$1.7B
$985.3M
Q2 24
$1.6B
$987.4M
Q1 24
$1.5B
$988.4M
Debt / Equity
NEWT
NEWT
ZLAB
ZLAB
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
Q2 24
2.38×
Q1 24
2.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEWT
NEWT
ZLAB
ZLAB
Operating Cash FlowLast quarter
$-579.2M
$-26.0M
Free Cash FlowOCF − Capex
$-579.3M
$-26.7M
FCF MarginFCF / Revenue
-790.0%
-21.0%
Capex IntensityCapex / Revenue
0.1%
0.5%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$-1.0B
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$-579.2M
$-26.0M
Q3 25
$-167.3M
$-32.0M
Q2 25
$-199.8M
$-31.0M
Q1 25
$-60.7M
$-61.7M
Q4 24
$-153.0M
$-55.8M
Q3 24
$-25.7M
$-26.8M
Q2 24
$2.9M
$-42.2M
Q1 24
$-38.7M
$-90.1M
Free Cash Flow
NEWT
NEWT
ZLAB
ZLAB
Q4 25
$-579.3M
$-26.7M
Q3 25
$-167.3M
$-35.0M
Q2 25
$-199.9M
$-33.9M
Q1 25
$-60.7M
$-63.2M
Q4 24
$-153.5M
$-58.4M
Q3 24
$-25.9M
$-28.2M
Q2 24
$2.9M
$-42.9M
Q1 24
$-38.7M
$-91.1M
FCF Margin
NEWT
NEWT
ZLAB
ZLAB
Q4 25
-790.0%
-21.0%
Q3 25
-223.3%
-30.4%
Q2 25
-284.7%
-31.1%
Q1 25
-91.6%
-59.9%
Q4 24
-203.6%
-53.8%
Q3 24
-41.2%
-27.7%
Q2 24
4.7%
-42.9%
Q1 24
-66.5%
-104.5%
Capex Intensity
NEWT
NEWT
ZLAB
ZLAB
Q4 25
0.1%
0.5%
Q3 25
0.0%
2.6%
Q2 25
0.1%
2.6%
Q1 25
0.1%
1.5%
Q4 24
0.6%
2.4%
Q3 24
0.4%
1.3%
Q2 24
0.1%
0.7%
Q1 24
0.1%
1.1%
Cash Conversion
NEWT
NEWT
ZLAB
ZLAB
Q4 25
-29.64×
Q3 25
-9.35×
Q2 25
-14.58×
Q1 25
-6.48×
Q4 24
-8.35×
Q3 24
-2.15×
Q2 24
0.27×
Q1 24
-4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEWT
NEWT

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons